TweenVax: a program to increase HPV vaccination in 9–12-year-olds
Official title: TweenVax: A Comprehensive Practice-, Provider-, and Parent/Patient-Level Intervention to Improve Adolescent HPV Vaccination
Run by Emory University · NCT07104240 · Data updated 2026-11-12
This project tests whether the TweenVax program—education and messaging for clinics, providers, parents, and patients—helps more unvaccinated 9–12-year-olds start the HPV vaccine series than usual care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 9 Years and up |
| Sex | All |
| Enrollment | 1836 (estimated) |
| Sponsor | Emory University Academic / other |
| Locations | 1 site (Atlanta, Georgia) |
| Status | Recruiting |
| Started | May 2, 2025 |
| Main results expected | March 6, 2027 |
| Study ends | March 6, 2028 |
| Registry record updated | September 3, 2026 |
| Trial ID | NCT07104240 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are unvaccinated 9–12-year-old children seeking care at participating community pediatric or family practice clinics.
✕Probably not a fit
Children who have already received any HPV vaccine dose, those outside the 9–12 age range, or those who do not receive care at an enrolled clinic are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This cluster-randomized trial assigns community pediatric and family practices to one of three arms: full TweenVax (practice, provider, parent and adolescent-level education with a tablet app), provider/practice-only components, or usual care. Practices must have sufficient patient volume and use electronic medical records or report to the state immunization registry so the team can track HPV vaccine initiation among 9–12-year-olds who have not yet received any HPV doses. The primary outcome is HPV vaccine initiation rates during the intervention with practices followed for up to one year after the intervention period. The intervention combines staff training, provider communication coaching, parent- and patient-facing messaging, and an internet-based TweenVax application used during clinical encounters.
Why it matters
Potential benefit: If successful, the program could increase HPV vaccine starts and completion by age 13, lowering future rates of HPV-related cancers.
How similar studies have gone: Prior pilot work and broader evidence that strong provider recommendations and parent education improve HPV uptake support this approach, though multi-component clinic-level packages remain under active testing at scale.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * PRACTICE-LEVEL: Must be community based primary care providers (pediatrics or family practice) * PRACTICE-LEVEL: Are willing to be part of the study * PRACTICE-LEVEL: Have sufficient patient population to support 51 adolescents aged 9-12 years over approximately a 9-month period * PRACTICE-LEVEL: Utilize an electronic medical records system and/or report to the state Immunization Information System (IIS) * CHILD/ADOLESCENT: Aged 9-12 years * CHILD/ADOLESCENT: Seeking care from an enrolled practice during the study period * CHILD/ADOLESCENT: Have not received any doses of HPV vaccine by the time of their first visit during the study period
Where it's running
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States Recruiting
Study contacts
- Principal investigator: Robert Bednarczyk, PhD — Emory University Hospital/Winship Cancer Institute
- Study coordinator: Robert Bednarczyk, PhD
- Email: rbednar@emory.edu
- Phone: 404-727-9713
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Interpersonal Communication and Vaccination Workflow Training in Pharmacies to Improve HPV Vaccination Recommendations
We’re testing whether training pharmacy staff in effective communication and vaccination workflows helps them recommend and provide HPV vaccines more consistently.
-
Testing a new vaccine to prevent HPV-related cancers in women
This study is testing a new vaccine to see if it can safely prevent HPV-related cancers in women aged 18 to 45.
-
MRI or CT planning to guide high-dose-rate prostate brachytherapy
This trial tests whether adding an MRI to CT-based treatment planning for HDR prostate brachytherapy changes urinary side effects in men with localized prostate cancer.
-
Fall Prevention Pathways: A digital program to help older adults reduce fall risk
A digital, remotely monitored 8-week program is being tested to see if it can reduce fall risk in community-dwelling adults aged 65–85 who are at low to moderate risk.
-
Mobile health navigation to improve breast cancer screening in Kenyan women
This study tests m-Health patient navigation tools to help women in Kenya access breast cancer screening and early detection services.
-
Moving Yourself in Space and Time: MYSTIC
This study tests a music-based stepping therapy to see if people with Parkinson's disease benefit from learning new steps and rhythms set to music.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.